Complex I inhibition combined with TLR activation in the breast tumor microenvironment educates cytotoxic neutrophils
Open Access
- 11 July 2025
- journal article
- cancer
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (28) , eadu5915
Abstract
Although effective for immunologically hot tumors, immune checkpoint inhibitors minimally affect tumors that are not T cell inflamed, including breast cancer. An alternate strategy to combat immune cold breast tumors may be to reeducate innate immunity. This study identifies strategies to skew neutrophils to acquire tumoricidal properties. Systemic Toll-like receptor (TLR)–induced inflammation, concomitant with mitochondrial complex I inhibition in breast tumors, increases neutrophil cytotoxicity against breast cancer cells and independently of CD8+ T cell immunity. These therapy-entrained neutrophils enhance secretory granule production, increasing expression of the reduced form of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase machinery and inducing a respiratory burst. Moreover, systemic administration of TLR agonists elevates nuclear factor κB signaling in neutrophils to increase production of secretory granule and NADPH oxidase machinery components, whereas complex I inhibitors are required to potentiate oxidative damage. In summary, we describe a class of neutrophils, educated by the combined action of inflammatory mediators and metabolic inhibitors, having tumoricidal functions.Keywords
This publication has 93 references indexed in Scilit:
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic MelanomaNew England Journal of Medicine, 2011
- In vivo imaging of reactive oxygen and nitrogen species in inflammation using the luminescent probe L-012Free Radical Biology and Medicine, 2009
- Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvantJournal of Experimental Medicine, 2009
- The endogenous Toll–like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancerJournal of Leukocyte Biology, 2009
- Mitochondrial Respiratory Complex I Regulates Neutrophil Activation and Severity of Lung InjuryAmerican Journal of Respiratory and Critical Care Medicine, 2008
- Polarized immune responses differentially regulate cancer developmentImmunological Reviews, 2008
- Endocytic pathways regulate Toll‐like receptor 4 signaling and link innate and adaptive immunityThe EMBO Journal, 2006
- INNATE IMMUNE RESPONSE IN TH1- AND TH2-DOMINANT MOUSE STRAINSShock, 2004
- Decreased Expression of Toll-Like Receptor-4 and MD-2 Correlates with Intestinal Epithelial Cell Protection Against Dysregulated Proinflammatory Gene Expression in Response to Bacterial LipopolysaccharideThe Journal of Immunology, 2001
- Differential Expression and Regulation of Toll-Like Receptors (TLR) in Human Leukocytes: Selective Expression of TLR3 in Dendritic CellsThe Journal of Immunology, 2000